CorMedix Inc. (CRMD)
NASDAQ: CRMD · Real-Time Price · USD
9.81
+0.16 (1.66%)
Nov 28, 2025, 1:00 PM EST - Market closed
CorMedix Revenue
CorMedix had revenue of $104.28M in the quarter ending September 30, 2025, with 810.22% growth. This brings the company's revenue in the last twelve months to $214.30M, up 1,647.67% year-over-year. In the year 2024, CorMedix had annual revenue of $43.47M.
Revenue (ttm)
$214.30M
Revenue Growth
+1,647.67%
P/S Ratio
3.10
Revenue / Employee
$3,296,980
Employees
65
Market Cap
772.92M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 43.47M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 65.41K | -125.53K | -65.74% |
| Dec 31, 2021 | 190.94K | -48.30K | -20.19% |
| Dec 31, 2020 | 239.23K | -44.04K | -15.55% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CRMD News
- 15 days ago - CorMedix: Raised Guidance, NOL Confidence, And Rezzayo Optionality Justify A Hold Rating - Seeking Alpha
- 17 days ago - Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 17 days ago - CorMedix Q3 Profit Soars As DefenCath Dialysis Demand Exceeds Expectations - Benzinga
- 17 days ago - CorMedix Inc. (CRMD) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 17 days ago - CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance - GlobeNewsWire
- 4 weeks ago - CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025 - GlobeNewsWire
- 5 weeks ago - CorMedix: Strong Buy After Strong Developments And A Strategy Before Earnings - Seeking Alpha
- 5 weeks ago - CorMedix Inc. Receives Innovative Technology Designation From Vizient for DefenCath - GlobeNewsWire